Identifying Predictors of Weight‐Related Outcomes With Fixed‐Dose, Extended‐Release Naltrexone and Bupropion Among Treatment‐Adherent Patients in Phase 3 COR Trials: A Treatment Target Analysis (Obesity Science & Practice, 2026)